Follow us on Twitter
twitter icon@FreshPatents


Psychiatric Disorders patents

      

This page is updated frequently with new Psychiatric Disorders-related patent applications.




 Novel tricyclic modulators of cannabinoid receptors patent thumbnailNovel tricyclic modulators of cannabinoid receptors
The compounds of the invention are modulators of cannabinoid receptors cb1 or cb2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases.
The University Of Montana


 Peptides as oxytocin agonists patent thumbnailPeptides as oxytocin agonists
The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.


 Peptides as oxytocin agonists patent thumbnailPeptides as oxytocin agonists
The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.


 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives patent thumbnail5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives
The present invention relates to compounds of formula of formula i wherein x, ar, r1, m and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.


 (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders patent thumbnail(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


 Process for the preparation of histamine h3 receptor modulators patent thumbnailProcess for the preparation of histamine h3 receptor modulators
The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. .
Janssen Pharmaceutica Nv


 Extracranial implantable devices,  the treatment of neuropsychiatric disorders patent thumbnailExtracranial implantable devices, the treatment of neuropsychiatric disorders
The present disclosure relates to methods, devices, and systems used for the treatment of mood, anxiety, cognitive, and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“tns”). More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein..
Neurosigma, Inc.


 Pharmaceutical salts of an orexin receptor antagonist patent thumbnailPharmaceutical salts of an orexin receptor antagonist
The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.


 Morpholin-pyridine derivatives patent thumbnailMorpholin-pyridine derivatives
The present invention relates to compounds of formula of formula i wherein x, r, l, ar, r1 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.


 Cb2 receptor ligands for the treatment of psychiatric disorders patent thumbnailCb2 receptor ligands for the treatment of psychiatric disorders
The present invention provides cannabinoid type 2 (cb2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-o-methylhonokiol for treating attention deficit hyperactivity disorder (adhd) and tourette's syndrome..
Ariel - University Research And Development Company, Ltd.


System and diagnosis and treatment of neuropsychiatric disorders

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered bh4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder.
The Research Foundation For Mental Hygiene, Inc.

Guanidine compounds and use thereof as binding partners for 5-ht5 receptors

Corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-ht5 receptors for the treatment of diseases which are modulated by a 5-ht5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions..

Methods and compositions for the treatment of post-traumatic stress disorder

Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (ptsd). In particular, described herein are angiotensin receptor blockers (arbs), and in particular the combination of one or more arb (such as telmisartan) and an agent that enhances the delivery of the arb across the blood-brain barrier (such as minocycline).

Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Halogenated quinazolin-thf-amines as pde1 inhibitors

The present invention provides halogenated quinazolin-thf-amines as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

In one aspect, the invention relates to n-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Compositions and methods for treatment of psychiatric disorders

Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain l-methionine..

In vitro diagnosing parkinson's disease

The present invention relates to an in vitro method of diagnosing a neurological disease associated with at least one symptom selected from the group comprising non-motor symptoms, sleep-wake disorders, sensory disorders, neuropsychiatric disorders and cognitive difficulties, comprising measuring the amount of active c-rel factor in a biological sample comprising endogenus c-rel factor from a patient.. .
Fondezione Ospedale Hospital In Venice

Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions..
Max-planck-gesellschaft Zur Forderung Der Wissensc Haften E.v.

1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

And pharmaceutically acceptable salts thereof, wherein a, ra, r1, r2, r3, r4, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..

2-pyridyloxy-4-methyl orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-4-methyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-methyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Hexahydrofuropyrroles as pde1 inhibitors

The present invention provides hexahydrofuropyrroles as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Compositions and methods for the treatment of addiction and other neuropsychiatric disorders

The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (hpa) axis and at least one active ingredient that targets the prefrontal cortex.
Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College

Lithium co-crystals for treatment of neuropsychiatric disorders

The invention concerns methods and compositions for treating a neuropsychiatric disorder, wherein the method comprises administering an effective amount of a co-crystal of lithium to a subject in need thereof, wherein the co-crystal comprises lithium, or a pharmaceutically acceptable salt thereof, and an amino acid.. .
University Of South Florida

N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders

The present invention relates to compounds of the general formula i wherein het, r1, r2, w and x are as defined herein. Compounds of formula i are useful for treating neuropsychiatric disorders..
Hoffmann-la Roche Inc.

Piperidinyloxy lactone orexin receptor antagonists

The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Imidazopyrazinones as pde1 inhibitors

The present invention provides imidazopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Diazepane orexin receptor antagonists

The present invention is directed to diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the diazepane compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Quinazolin-thf-amines as pde1 inhibitors

The present invention provides quinazolin-thf-amines as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

2-amino-3-ester-pyridyl orexin receptor antagonists

The present invention is directed to 2-amino-3-ester pyridyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-amino-3-ester pyridyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Thioether-piperidinyl orexin receptor antagonists

The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Heterocyclic compounds for the treatment of neurological and psychological disorders

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Alkermes Pharma Ireland Limited

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Monitoring device and cognitive behavior therapy

A user monitoring device system includes a user monitoring device with a microphone and sensors to determine air quality, sound level/quality, light quality and ambient temperature near the user. A movement detection device detects a user's movement information.
Hello Inc.

Mlk inhibitors and methods of use

Provided are compounds having an inhibitory effect on mixed lineage kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by mixed lineage kinase inhibition.
The University Of Rochester

Imidazotriazinones as pde1 inhibitors

The present invention provides imidazotriazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

2-pyridyloxy-3-ester-4-ether orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-3-ester-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

A pyrimidine derivative and a fatty acid source for use in the treatment of constipation

The invention relates to a combination of a pyrimidine derivative and a fatty acid source for use in the treatment of constipation, in particular in the treatment of constipation in patients suffering from gi disorders, neurological disorders, or psychiatric disorders. Advantageously, the combination comprises one or more vitamins or fibres..
N.v. Nutricia

Quinoline derivatives as pde10a enzyme inhibitors

The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10a over other pde subtypes.
H. Lundbeck A/s

Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Selective fkbp51 ligands for treatment of psychiatric disorders

The present invention relates to compounds of the general formula (i) having a selective fkbp51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective fkbp51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions..
Max-planck-gesellschart Zur FÖrderung Der Wissensc Haften E.v.

Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

And pharmaceutically acceptable salts thereof, wherein ring b, a1, a2, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..

Imidazole derivatives

As defined herein before useful for the treatment of psychiatric disorders.. .

Maternal th17 cells and psychiatric disorders

Methods are presented herein for reducing the risk of developing a psychiatric disorder (e.g., autism like disorder) in a fetus involving administering an inhibitor of t helper 17 (th17) cell activity to the mother of the fetus, while the mother is pregnant with the fetus at risk. Also encompassed herein is a method for treating a fetus in utero to reduce the risk of abnormal cortical development that arises from th17 cell-mediated activity..

5-ht3 receptor antagonists

Which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..

Polypeptides and methods for modulating d1-d2 dopamine receptor interaction and function

The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal d1-d2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from d1-d2 coupling and/or activation.
Centre For Addiction And Mental Health

Method and computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases

Computer modeling of interactions between and among cortico and subcortical areas of the human brain predicts the effect of drugs in psychiatric and cognitive diseases on one or more clinical scales. Diseases that can be modeled include psychiatric disorders, such as schizophrenia, bipolar disorder, major depression, adhd, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits therein and neurological disorders such as alzheimer's disease, mild cognitive impairment, parkinson's disease, stroke, vascular dementia, huntington's disease, epilepsy and down syndrome.

2-pyridyloxy-4-ester orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders

Copolymer 1, a copolymer 1-related peptide, a copolymer 1-related polypeptide, and t cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.. .
Yeda Research And Development Co. Ltd.

Orexin receptor antagonists

The disclosures herein relate to novel compounds of formula wherein w, x and y1, y2, y3 and y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.. .
Heptares Therapeutics Limited



Psychiatric Disorders topics:
  • Psychiatric Disorders
  • Psychiatric
  • Neurological
  • Dysfunction
  • Depressive Disorder
  • Major Depressive Disorder
  • Schizophrenia
  • High Altitude
  • Modulation
  • Antagonist
  • Treatments
  • Cingulate Cortex
  • Refractory
  • Anterior Cingulate Cortex
  • Complement Factor I


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Psychiatric Disorders for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Psychiatric Disorders with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4379

    file did exist - 2904

    1 - 1 - 51